Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Composite preparations for curing schemic brain damage

A technology for ischemic brain injury and preparations, applied in the direction of drug combinations, medical preparations containing active ingredients, organic active ingredients, etc., can solve cardiovascular function inhibition and central nervous system dysfunction, induce gastrointestinal reactions, safety Narrow scope and other issues, to achieve the effect of improving curative effect, improving neurobehavioral disorders, and reducing adverse reactions

Inactive Publication Date: 2008-05-14
SUZHOU UNIV
View PDF1 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the main problems in the clinical application of lithium salts are: narrow safety range, many and severe adverse reactions, which may induce gastrointestinal reactions, cardiovascular function inhibition and central nervous system dysfunction

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composite preparations for curing schemic brain damage
  • Composite preparations for curing schemic brain damage
  • Composite preparations for curing schemic brain damage

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0035] Example 1: A combined preparation for treating ischemic brain injury

[0036] 1. Animals and Grouping

[0037] Healthy SD rats, weighing 280-310g, were divided into 7 groups, 6 rats in each group, divided into: sham operation group, model group, PGE1(L), PGE1(S), Li, PGE1(L)+Li and PGE1 (S)+Li total 7 groups. PGE1(S) group was given 22.6nmol / kg PGE1 intravenous infusion immediately after ischemia; PGE1(L) group was given 45.2nmol / kg PGE1 intravenous infusion immediately after ischemia, the speed was 1ml / h. The Li group was given subcutaneous injection of 0.5mmol / kg lithium chloride, divided into two administrations, once 24 hours before ischemia, and once half an hour before ischemia, and the PGE1(S)+Li group was given 22.6nmol / kg PGE1 intravenous infusion and 0.5mmol / kg lithium chloride subcutaneous injection were given twice; PGE1(L)+Li group was given 45.2nmol / kg PGE1 intravenous infusion and 0.5mmol / kg lithium chloride twice hypodermic injection. The kg in mol / k...

Embodiment 2

[0062] Example 2: A combination preparation for treating ischemic brain injury

[0063] 1. Animals and Grouping

[0064] Healthy SD rats, weighing 280-310g, were divided into 6 groups, 8 in each group, namely: model group, PGE1 (L) with PGE1 intravenous infusion 45.2nmol / kg, PGE1 (S) with PGE1 intravenous infusion 22.6nmol Lithium chloride intravenous infusion 0.5mmol / kg, PGE1(L)+Li MIX (45.2nmol / kg+0.5mmol / kg) intravenous infusion mixture and PGE1(S)+Li (22.6nmol / kg +0.5mmol / kg) intravenous infusion mixture in 6 groups. PGE1, lithium chloride and PGE1+Li mixture were administered immediately after ischemia. The mixture was intravenous infusion at a speed of 1ml / h.

[0065] The doses of the above drugs are the doses used in animal experiments. When it comes to adults, the dose standard for adults should be about one-fifth to one-seventh of the dose for rats, and the dose standard for children should be used for children.

[0066] 2. Establishment of permanent focal middle ce...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a compound preparation for treating the ischemic brain damage; wherein, the active component comprises prostaglandin E1 the lithium salt; the prostaglandin E1 and the lithium salt can be mixed into the intravenous injection or infusion mixture, and the prostaglandin E1 also can be made into the intravenous injection or infusion agent, meanwhile the lithium salt can be made into the subcutaneous injection. The invention has the advantages of enabling to be used on the people needing treatment or the experiment animal, inducing the formation of the heat shock protein, protects the neuron, increasingg the resistance of the cell hypoxia, and resisting the ischemic brain damage function through the synergistic interaction of the prostaglandin E1 and the lithium salt compound preparation. The invention also has an advantage that: the application dosage of two medicines in the prostaglandin E1 and the lithium salt compound preparation are both lower than the convention dosage of the two medicine in the clinic, so as to reduce the adverse reaction and improve the curative effect. The invention provides a new compound preparation for the ischemic cerebral apoplexy.

Description

technical field [0001] The invention relates to a combined preparation for treating ischemic brain injury, through the synergistic effect of the combined preparation of prostaglandin E1 and lithium salt, it can induce the generation of heat shock protein, protect nerve cells, increase the tolerance of cells to hypoxia, resist Cerebral ischemic injury. Background technique [0002] Cerebral stroke, also known as stroke or cerebrovascular accident, is a group of diseases with cerebral ischemia or hemorrhagic injury symptoms as the main clinical manifestation, mainly divided into hemorrhagic stroke (cerebral hemorrhage and subarachnoid hemorrhage) There are two types of hemorrhagic stroke (cerebral infarction and cerebral thrombosis), among which ischemic stroke is the most common. The disease has an acute onset and a high fatality rate, and is one of the most important fatal diseases in the world. According to statistics, there are 1.2-1.5 million new cases of complete cereb...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K33/14A61K31/5575A61P9/10A61P25/00
Inventor 秦正红韩蓉盛瑞
Owner SUZHOU UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com